View Profile

Grant Support

Start year End year Title Source Position
1. 2014 An open-label study of the diagnostic and therapeutic utility of intravenous adenosine in the management of paroxysmal tachyarrhythmias Biomedical Research Support Grant, Medical College of Pennsylvania Co-Investigator
2. 2014 Comparison of DL- and D-sotalol in patients with malignant ventricular arrhythmias Bristol-Myers Squibb Co-Investigator
3. 2014 Response evaluation of site optimization of LV lead in MI patients Medtronic Co-Investigator
4. 2014 Implantable pharmacologic atrioverter (IPA). Pharmatarget Principal Investigator
5. 2009 Steering Committee HBI-3000 in AF. Huya Principal Investigator
6. 2009 Steering Committee Ranolazine in AF. CVT Principal Investigator
7. 2008 Steering Committee Om-8: Lovaza for AF. GSK Co-Investigator
8. 2008 Celviarone for ventricular arrhythmia Sanofi Principal Investigator
9. 2005 2008 Cardiac repolarization and sudden death Greenfield Foundation Co-Investigator
10. 2004 2008 Cellular and ionic mechanisms for T wave alternans in left ventricular hypertrophy AHA Co-Investigator
11. 2007 Mechanisms and clinical manifestations of arrhythmia W.W. Smith Charitable Trust Principal Investigator
12. 2004 2005 Efficacy & Safety of SSR 149744 in patients with AF Sanofi-Synthelabo Principal Investigator
13. 2003 2005 Effect of RSD-1235 on acute conversion of atrial fibrillation/flutter to sinus rhythm Cardiome Principal Investigator
14. 2000 2004 Dual chamber and VVI implantable defibrillator (DAVID). St. Jude Medical Co-Investigator
15. 2001 2002 Use of CVT-510 for ventricular rate control in atrial fibrillation Cardiovascular Therapeutics Co-Investigator
16. 2001 2002 Cellular basis for T wave alternans in ventricular hypertrophy. Sharpe Foundation Co-Principal Investigator
17. 2000 2002 Safety and efficacy of aqueous intravenous amiodarone in patients with malignant ventricular arrhythmia Wyeth Ayerst Labs Principal Investigator
18. 2000 2002 Conversion and maintenance of sinus rhythm using oral azimilide Procter and Gamble Pharmaceuticals Principal Investigator
19. 1997 2002 INVEST-Calcium channel blocker therapy in patients with ischemic heart disease. Knoll Member Steering Committee
20. 1997 2002 INVEST-Calcium channel blocker therapy in patients with ischemic heart disease. Knoll Regional Principal Investigator
21. 1997 2002 Sudden cardiac death heart failure trial (SCD HeFT) National Institutes of Health Co-Investigator
22. 1997 2002 INVEST-Calcium channel blocker therapy in patients with ischemic heart disease. Knoll Endpoint Committee
23. 2000 2001 Advanced elements of pacing trial (ADEPT). Medtronic Co-Investigator
24. 2000 2001 Electrophysiologic effects of Aqueous Amiodarone Wyeth Ayerst Labs Principal Investigator
25. 2000 2001 Effect of 2D-4522 on repolarization and refractoriness in an animal myocardial wedge and proarrhythmia potential preparation AstraZeneca Co-Investigator
26. 2000 2001 Effect of 237376 on repolarizaiton and refractoriness in a rabbit and dog ventricular wedge preparation SmithKline Beecham Pharmaceuticals Co-Investigator
27. 1997 2001 Carvedilol in patients with class IV heart failure SmithKline Beecham Co-Investigator
28. 1996 2001 Atrial fibrillation follow-up investigation of rhythm management (AFFIRM). National Institute of Health Co-Investigator
29. 2000 Comparison of medical therapy, pacing and defibrillation in chronic heart failure (COMPANION) Guidant Co-Investigator
30. 1999 2000 Dronedarone in patients with implantable defibrillators Sanofi Pharmaceuticals Principal Investigator
31. 1999 2000 Effect of TNF-antagonist on outcomes after cardiac surgery Immunex Co-Investigator
32. 1999 2000 METEOR: SB237376 for prevention of AF recurrence SmithKline Beecham Principal Investigator
33. 1999 2000 Ablation for focal AF Cardima Co-Investigator
34. 1997 2000 Tedisamil for termination and prevention of atrial fibrillation/flutter Solvay Pharmaceuticals Principal Investigator
35. 1997 2000 PNU-108342 for acute termination of atrial fibrillation/flutter Pharmacia Upjohn Principal Investigator
36. 1995 2000 Prevention of events with ace-inhibition (PEACE). NHLBI of NIH Co-Investigator
37. 1995 2000 The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). National Institute of Health Co-Investigator
38. 1995 2000 Mode selection trial in sinus node dysfunction (MOST). National Institutes of Health Co-Investigator
39. 1999 The evaluation of SB 237376 for its electrophysiological properties and potential risk for the development of proarrhythmias SmithKline Beecham Co-Investigator
40. 1997 1999 Intravenous amiodarone for in-hospital cardiac arrest victim (ALERT). Wyeth-Ayerst Principal Investigator
41. 1993 1999 Multicenter ICD trial (AVID). National Institutes of Health Co-Investigator
42. 1995 1997 Clinical outcomes in patients with post-operative arrhythmias (COPPA) II: Propafenone prophylaxis Knoll Pharmaceuticals Principal Investigator
43. 1992 1996 Multicenter unsustained tachycardia trial (MUSTT). National Institutes of Health Co-Investigator
44. 1995 An open label, dose-range study of the effects of BRL32872A on electrophysiologic electrocardiographic hemodynamic and safety parameters when administered intravenously to patients undergoing electrophysiologic evaluation. SmithKline Beecham Principal Investigator
45. 1994 1995 Use of sotalol as adjuvant therapy in patients with arrhythmia control devices Berlex Co-Investigator
46. 1994 1995 A randomized, double-blind comparison of ibutilide versus procainamide for termination of atrial fibrillation/flutter Upjohn Principal Investigator
47. 1994 1995 Transvenous defibrillation and tiered ICD therapy En Guard Telectronics Co-Investigator
48. 1994 1995 Active can vs. Jewel for treatment of malignant arrhythmias Medtronic Co-Investigator
49. 1994 1995 New England Atrial Fibrillation Trial (NAFIT). Knoll Pharmaceuticals Co-Investigator
50. 1994 1995 Intravenous ibutilide for termination of atrial fibrillation or flutter after coronary artery surgery Upjohn Principal Investigator
51. 1993 1995 Clinical outcome in patients with post-operative arrhythmia (COPPA); beta-blocker prophylaxis Wyeth-Ayerst Laboratories Principal Investigator
52. 1993 1995 Use of intravenous mexiletine for suppression of inducible ventricular arrhythmia Boehringer-Ingelheim Principal Investigator
53. 1994 1994 New catheter ablation designer for radiofrequency ablation Webster Co-Investigator
54. 1994 1994 Phase I trial of a universal pacemaker device - TheraDR Medtronics Co-Investigator
55. 1993 1994 Effect of propafenone on defibrillation thresholds Knoll Pharmaceuticals Principal Investigator
56. 1993 1994 Use of a transvenous lead system in ICD utilization Medtronic Co Co-Investigator
57. 1991 1994 Use of ibutilide in patients with inducible sustained VT. Upjohn Company Principal Investigator
58. 1991 1994 Ventak-P2 and PRX arrhythmia control device CPI Co-Investigator
59. 1991 1994 Intravenous ibutilide for the termination of spontaneous atrial fibrillation/flutter. Upjohn Company Principal Investigator
60. 1990 1994 Randomized, multiple dose study of IV amiodarone in patients with malignant ventricular arrhythmia Wyeth Laboratories Principal Investigator
61. 1991 1992 Effect of left ventricular hypertrophy on defibrillator thresholds CPI Principal Investigator
62. 1991 1992 Bidisomide infusion for termination of laboratory induced supraventricular arrhythmia Searle Laboratories Principal Investigator
63. 1991 1992 Electrophysiologic and hemodynamic effects of trandolapril in a feline model of LVH. Knoll Pharmaceuticals Principal Investigator
64. 1991 1992 Parallel assessment of the proarrhythmic potential of Class I drugs in a chronic feline infarction model Knoll Pharmaceuticals Principal Investigator
65. 1990 1992 Res-Q arrhythmia control device Intermedics Co-Investigator
66. 1991 1991 Use of intravenous mexiletine in combination with Class I antiarrhythmic agents tested in the electrophysiology laboratory Boehringer-Ingelheim Principal Investigator
67. 1990 1991 Guardian arrhythmia control device Telectronics Co-Investigator
68. 1990 1991 Basic investigation of the electrophysiologic and antifibrillatory effects of a new Class III antiarrhythmic drug Wyeth-Ayerst Research Laboratories Principal Investigator
69. 1990 1991 Intravenous captopril plus TPA after acute MI Squibb Co-Investigator
70. 1989 1991 Evaluation of zofenopril in patients with congestive heart failure Squibb Co-Investigator
71. 1989 1991 Ventricular tachycardia cooperative study Mary L. Smith Charitable Trust Principal investigator
72. 1987 1991 Multicenter study of captopril after myocardial infarction (SAVE). Squibb Investigator
73. 1989 1990 Non-invasive programmed stimulation using permanent cardiac pacemakers Intermedics, Inc Co-Investigator
74. 1989 1990 Effects of potassium channel blockade on ischemic myocardial arrhythmias Southeastern Pennsylvania affiliate, American Heart Association Co-Investigator
75. 1989 1990 Glyburide effects on ventricular vulnerability and refractoriness in a feline ischemia model Upjohn, Inc Co-Investigator
76. 1989 1990 A PES study of intravenous and oral sematilide in patients with documented sustained ventricular tachycardia/ventricular fibrillation, with long-term follow-up Berlex Laboratories Co-Investigator
77. 1989 1990 Electrophysiologic abnormalities related to left ventricular hypertrophy: Effects of calcium channel blockade Knoll Pharmaceutical, Inc Principal Investigator
78. 1986 1990 Drug treatment of depression in the institutionalized aged. National Institutes of Health, Public Health Service, 1986-1990 (lROlMH41489-01). Co-investigator
79. 1988 1989 Anti-tachycardia pacing for ventricular tachycardia Intermedics Co-Investigator
80. 1988 1989 Recainam versus encainide for inducible sustained ventricular tachycardia Wyeth Laboratories Principal investigator
81. 1988 1989 Antiarrhythmic effects of recainam on spontaneous ventricular ectopy Wyeth Principal investigator
82. 1988 1989 Open-label study of intravenous amiodarone Wyeth Laboratories Principal Investigator
83. 1988 1989 Basic electrophysiologic and antifibrillatory effects of WY48,986 Wyeth Laboratories Principal Investigator
84. 1988 1989 Electrophysiologic effects of left ventricular hypertrophy in vivo American Heart Association Southeastern Pennsylvania Chapter Co-Investigator
85. 1987 1988 Electrophysiologic effects of recainam in the canine atrium Wyeth Co-investigator
86. 1986 1988 Evaluation of cilazopril in patients with congestive heart failure Hoffman-LaRoche Co-investigator
87. 1986 1987 Hemodynamic evaluation of nicorandil Upjohn Co Principal Investigator
88. 1986 1987 Open and out-patient evaluation of the safety and efficacy of oral and intravenous recainam (WY42,362) in suppression of inducible ventricular tachyarrhythmias Wyeth Laboratories Principal Investigator
89. 1985 1986 Evaluation of the electrophysiologic properties of WY-42,362 (Recainam) in hospitalized patients with tachyarrhythmias Wyeth Laboratories Principal Investigator
90. 1985 1986 Effect of prostaglandin El on electrophysiologic properties in the human Heart Upjohn Co Principal Investigator
91. 1985 1986 Effect of products of arachidonic acid pathway on vulnerability to ventricular fibrillation Fellowship Grant. Southeastern Pennsylvania Chapter, American Heart Association Co-investigator
92. 1985 1986 Basic investigation into the pathogenesis of sudden cardiac death Fannie Rippel Foundation Grant Principal Investigator
93. 1985 1986 Reperfusion ventricular fibrillation in the feline model Pharmaceutical Manufacturer's Association Foundation Co-Investigator
94. 1984 1986 Effect of a thromboxane synthetase inhibitor on arrhythmia inducibility in a chronic cat infarction model Upjohn Co Principal Investigator
95. 1983 1985 Automatic Implantable Defibrillator Fannie E. Rippel Foundation Co-investigator
96. 1984 Effect of contrast agents on ventricular repolarization and arrhythmia Berlex Corp Principal Investigator
97. 1984 Use of an oral beta-agonist for treatment of refractory heart failure SKF Co-Investigator
98. 1983 1984 Effect of a thromboxane-synthetase inhibitor on VF threshold CIBA-GEIGY Pharmaceuticals Co-Investigator
99. 1982 1984 Use of bethanidine for the treatment of ventricular arrhythmia A.H. Robins Co., Richmond, VA Principal Investigator
100. 1981 1984 Encircling endocardial ventriculotomy National Institute of Health Co-Investigator
101. 1983 Effect of pacing site and cycle length on dispersion of refractoriness Medtronic Corp Co-Investigator
102. 1983 Efficacy of nadalol in suppressing electrically induced supraventricular tachycardia Squibb and Company Principal Investigator
103. 1983 Research Award for Basic Animal Research Coonrad Memorial Fund Fellowship Recipient
104. 1982 Use of Versatrax AV sequential pacemaker Medtronics, Inc Principal Investigator

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.